Date Added: 08/02/2017
Date Updated: 08/02/2017
Rapid sepsis detection
Specialties: Haematology & blood products - Infectious disease, microbiology & GUM
Technology Type: Diagnostics
Stage of development: Information not available
Stage of EAA: Assessment Complete
There is an urgent need for a diagnostic test to enable the rapid identification and diagnosis of sepsis, especially in patients presenting to emergency departments.
The T2Candida test reported good sensitivity and specificity, however, given the low incidence of candida septicaemia, it is unlikely to be cost-effective. HealthPACT noted that the T2Candida test would be efficacious in some immuno-compromised and oncology patients, however, its need in clinical practice is likely to be minimal. No further research on the T2Candida test on behalf of HealthPACT is warranted at this time.
The evidence-base for rapid sepsis tests such as the IRIDICA remains immature. HealthPACT does not support public investment in technologies such as this in clinical practice at this time and recommends that an overview of all sepsis detection technologies be commissioned.